Table 1.
Major classes of therapeutic agents inducing permanent hearing loss (with examples and citations)
| Class | Examples | References |
|---|---|---|
| Platinum-based therapeutics | Cisplatin, carboplatin, oxaliplatin | Brock et al. 2012; Karasawa and Steyger 2015 |
| Aminoglycosides (AGs) | Amikacin, gentamicin, kanamycin, tobramycin | Miller 1985; Schacht et al. 2012; Jiang et al. 2017 |
| Peptide antibiotics | Capreomycin, viomycin, chloramphenicol | Akbergenov et al. 2011; Kokong et al. 2014; Arnold et al. 2017 |
| Polypeptide antibiotics | Vancomycin (especially synergistically with AGs) | Brummett et al. 1990; Lestner et al. 2016; Garinis et al. 2018 |
| Macrolides | Erythromycin | Miller 1985; Brummett 1993 |
| Cyclodextrins (vehicle) | Derivatives of cyclodextrins, for Niemann–Pick syndrome type 1C | Crumling et al. 2017 |
| Antimalarials | Chloroquine | Bortoli and Santiago 2007; Kokong et al. 2014 |
| Loop diuretics (esp. synergistic with AGs and cisplatin) | Furosemide, bumetanide | Rybak 1993 |
| Nonopioid analgesics | Acetaminophen = paracetamol | Yorgason et al. 2010 |
| Antineoplastics | Vincristine(?) | Lugassy and Shapira 1996 |